GSK plc has partnered with Alfasigma, granting them exclusive worldwide rights to develop and market linerixibat, an investigational drug for cholestatic pruritus in primary biliary cholangitis, with a $300 million upfront payment and potential total earnings of up to $670 million depending on regulatory approvals and sales milestones. The agreement was announced on March 9, 2026, emphasizing GSK's focus on advancing liver disease treatments.